# Losing Weight Predicted More Heart Attacks

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks

> A prespecified analysis of 17,604 people found semaglutide's cardiovascular protection largely independent of weight lost. In the placebo arm, losing weight predicted more cardiac events.

## Key points

- No linear relationship between week-20 weight loss and later heart attacks or strokes.
- Waist reduction explained only ~33% of the benefit.
- In the PLACEBO arm, weight loss was associated with MORE cardiac events, which points to reverse causation inside an RCT.
- Benefit appeared across every baseline weight and waist category, which is reassuring for slow responders.
- Waist tracked the benefit; weight did not.
- Novo Nordisk funded; the 33% is a mediation estimate.

A prespecified analysis of 17,604 people in the SELECT trial asked whether semaglutide’s protection against heart attacks came from the weight it removed. The answer was mostly no.[1] And in the placebo group, the same analysis found that **losing weight was associated with *more* cardiovascular events**. That second finding is the more instructive of the two.

## The benefit did not follow the weight

Everyone in SELECT was at least 45, carried a BMI of 27 or more, and had heart disease already diagnosed; none had diabetes. Across 41 countries, half drew weekly semaglutide at 2.4 mg and half a placebo. This analysis looked inside that result to ask what the protection tracked.

- **Benefit appeared across every baseline category** of body weight and waist circumference. Heavier and lighter participants gained similarly.
- **Weight lost by week 20 showed no linear relationship** to heart attacks and strokes afterward.
- **Waist reduction did track it**, both at week 20 and over 104 weeks.
- **An estimated 33% of the benefit was mediated through waist reduction** (hazard ratio 0.86, 95% CI 0.77–0.97 after adjusting for changes over time).

The authors’ own interpretation is that the cardioprotective effect was independent of baseline adiposity and of weight loss, with only a small association with waist circumference. That points to mechanisms beyond fat reduction. A model that [projected a 22% cut in heart risk for people who have never had heart disease](https://glpwatchdog.org/research/a-benefit-nobody-observed) rests on the opposite assumption, routing the whole benefit through five risk factors.

> Two-thirds of the heart benefit is not explained by anything the scale or the tape measure recorded.

That waist matters while weight does not is itself informative. Waist circumference tracks visceral fat (the metabolically active fat around the organs), while body weight lumps that together with muscle, bone and water. Two people losing the same weight can lose very different tissue, which is a recurring theme in this drug class.

We reached a similar conclusion from a much weaker analysis, a post-hoc mediation study in sleep apnea, in [is it just the weight loss](https://glpwatchdog.org/research/is-it-just-the-weight-loss). SELECT answers the same question with a prespecified analysis, in 17,604 people, against a hard endpoint.

## The sentence in the placebo column

> **Among people taking placebo, weight loss was *paradoxically associated with increased* cardiovascular risk.** That is worse than neutral, and it was measured the same way, over the same period, as in the semaglutide arm, where weight loss was harmless or helpful.

The likeliest explanation is a familiar one. When no drug is causing it, weight loss is often a sign of *illness*: developing cancer, heart failure, or the general decline that can precede a cardiac event. In that case weight falls because something is wrong. The weight loss is a symptom, and the cardiac event follows for the same underlying reason.

Epidemiologists call this reverse causation, and it is why decades of observational studies linking weight loss to worse outcomes were so hard to interpret. This instance stands out because of where it appeared: **inside a randomized controlled trial**, in the control arm, where it cannot be waved away as a defect of observational data.

> **Put the two arms side by side.** The trial, the outcome and the measurement are the same. In one arm, weight coming off is a drug working and carries no extra risk. In the other, weight coming off is a body failing and predicts harm. **A change on the scale cannot be read without knowing why it happened.**

The lesson applies beyond this trial. Any study that reports weight change as an outcome or a predictor, without establishing what caused it, is reporting an ambiguous quantity. Diet research leans on that quantity more than most, which makes [a Mediterranean diet trial that counted heart attacks instead](https://glpwatchdog.org/research/mediterranean-diet-the-outcome-trial) unusual.

## What it means practically

- **The cardiovascular benefit is not a reward for losing weight.** In SELECT, people who lost less were protected about as much as people who lost more.
- **That is reassuring for slow responders**, who often conclude the drug is not working.
- **Waist may be the better thing to watch** than weight, and it is the cheaper measurement.
- **Unexplained weight loss without a drug is a reason to see a doctor**, not a success.

Two limits belong with all of it. The trial was funded by Novo Nordisk, which makes semaglutide; that is ordinary, and [Cochrane’s semaglutide review](https://glpwatchdog.org/research/the-cochrane-verdict-and-who-funded-it) found most of the drug’s trials were paid for by its manufacturer. And the 33% mediation figure is a modeling estimate that rests on assumptions trial data cannot verify, the same caution that applies to every mediation analysis.

## Frequently asked questions

### Does semaglutide protect the heart because of the weight loss?

Mostly not. In a prespecified analysis of 17,604 SELECT participants, weight lost by week 20 showed no linear relationship with later heart attacks and strokes, and only about a third of the benefit was mediated through waist reduction.

### Why was weight loss linked to more heart events on placebo?

The likeliest reason is that, without a drug causing it, weight loss often signals illness: developing cancer, heart failure, or the decline preceding a cardiac event. In that case the weight loss is a symptom rather than a cause, which epidemiologists call reverse causation.

### Why does that matter so much?

Because it appeared inside a randomized trial, in the control arm, where it cannot be dismissed as an artifact of observational data. The same measurement in the same trial means opposite things depending on why the weight moved.

### Does this mean losing less weight on the drug is fine?

For cardiovascular protection, the trial found benefit across every baseline weight and waist category, and no linear relationship between early weight loss and later events. That is reassuring for people who respond slowly.

### Should I track my waist instead of my weight?

Waist reduction was the adiposity measure that tracked cardiovascular benefit in this analysis, while weight was not. It also reflects visceral fat rather than lumping fat together with muscle and water.

## References

1. Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. 2025. PMID: 41138739. https://pubmed.ncbi.nlm.nih.gov/41138739/

---

Cite as: GLP Watchdog, Nora Bissett, "Losing Weight Predicted More Heart Attacks", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks

Canonical HTML page: https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
